Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.76 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21141321 | 0.88 | TAS1R3 (0.63) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19987535 | 0.88 | TAS1R3 (0.67) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL702640 | 0.87 | TAS1R3 (1.00) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19987404 | 0.82 | TAS1R3 (0.89) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL25305806 | 0.81 | EPHX2 (0.58) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL17049551 | 0.81 | SMN1; SMN2 (0.73) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL8360543 | 0.78 | HSD17B10 (0.58) | SMN1; SMN2ALDH1A1MEN1KMT2APOLB | |
| SCHEMBL19472645 | 0.78 | LMNA (0.57) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL23652083 | 0.77 | TAS1R3 (0.48) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL19540526 | 0.77 | ALDH1A1 (0.60) | TAS1R3TAS1R1LMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399932-B2 | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer | IDO1, IDO2, INMT | TAS1R3 4806/4885TAS1R1 4776/4885LMNA 4373/4885 |
| US-20180079712-A1 | INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | IDO1, IDO2, INMT | TAS1R3 4806/4885TAS1R1 4776/4885LMNA 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.